

Kentaro Tanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9384827/publications.pdf>

Version: 2024-02-01

79
papers

2,989
citations

257429

24
h-index

175241

52
g-index

80
all docs

80
docs citations

80
times ranked

5484
citing authors

#	ARTICLE	IF	CITATIONS
1	Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 Protein. <i>Immunity</i> , 2009, 30, 80-91.	14.3	716
2	Suppressor of Cytokine Signaling-1 Is Essential for Suppressing Dendritic Cell Activation and Systemic Autoimmunity. <i>Immunity</i> , 2003, 19, 437-450.	14.3	209
3	Loss of Suppressor of Cytokine Signaling 1 in Helper T Cells Leads to Defective Th17 Differentiation by Enhancing Antagonistic Effects of IFN- γ on STAT3 and Smads. <i>Journal of Immunology</i> , 2008, 180, 3746-3756.	0.8	165
4	Generation of ROR γ t+ Antigen-Specific T Regulatory 17 Cells from Foxp3+ Precursors in Autoimmunity. <i>Cell Reports</i> , 2017, 21, 195-207.	6.4	120
5	Batf is important for IL-4 expression in T follicular helper cells. <i>Nature Communications</i> , 2015, 6, 7997.	12.8	114
6	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	2.2	100
7	Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells. <i>Journal of Immunology</i> , 2007, 179, 2170-2179.	0.8	96
8	Induction of Hyper Th1 Cell-Type Immune Responses by Dendritic Cells Lacking the Suppressor of Cytokine Signaling-1 Gene. <i>Journal of Immunology</i> , 2005, 174, 4325-4332.	0.8	90
9	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. <i>Lung Cancer</i> , 2018, 118, 36-40.	2.0	81
10	Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. <i>International Immunology</i> , 2008, 20, 753-762.	4.0	76
11	Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. <i>Lung Cancer</i> , 2018, 115, 116-120.	2.0	76
12	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. <i>Oncotarget</i> , 2017, 8, 68123-68130.	1.8	63
13	Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. <i>Lung Cancer</i> , 2020, 145, 18-26.	2.0	57
14	The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2006, 290, L971-L977.	2.9	53
15	Trim33 mediates the proinflammatory function of Th17 cells. <i>Journal of Experimental Medicine</i> , 2018, 215, 1853-1868.	8.5	48
16	Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. <i>Lung Cancer</i> , 2019, 130, 5-9.	2.0	44
17	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	2.5	42
18	Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)., 2020, 8, e000350.		42

#	ARTICLE	IF	CITATIONS
19	18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 13362.	3.3	39
20	Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by \pm 1 Nicotinic Acetylcholine Receptor-Mediated Activation in PC9 Cells. <i>Journal of Thoracic Oncology</i> , 2013, 8, 719-725.	1.1	37
21	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 75-82.	2.0	37
22	A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). <i>Journal of Thoracic Oncology</i> , 2021, 16, 2121-2132.	1.1	36
23	Pulmonary Suppressor of Cytokine Signaling-1 Induced by IL-13 Regulates Allergic Asthma Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 992-998.	5.6	35
24	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 152, 27-33.	2.0	35
25	Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. <i>International Journal of Cancer</i> , 2021, 149, 473-482.	5.1	35
26	Regulation of Pathogenic T Helper 17 Cell Differentiation by Steroid Receptor Coactivator-3. <i>Cell Reports</i> , 2018, 23, 2318-2329.	6.4	31
27	Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. <i>European Journal of Cancer</i> , 2021, 149, 14-22.	2.8	30
28	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 926-937.	1.1	27
29	Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. <i>Lung Cancer</i> , 2018, 120, 98-107.	2.0	23
30	Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. <i>Lung Cancer</i> , 2017, 112, 230-231.	2.0	22
31	CCAAT/Enhancer-Binding Protein \pm Negatively Regulates IFN- γ Expression in T Cells. <i>Journal of Immunology</i> , 2014, 193, 6152-6160.	0.8	21
32	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. <i>Lung Cancer</i> , 2020, 146, 97-104.	2.0	21
33	Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 145-150.	2.0	18
34	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. <i>International Immunology</i> , 2020, 32, 547-557.	4.0	18
35	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. <i>Oncotarget</i> , 2018, 9, 30587-30593.	1.8	18
36	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. <i>Cancer</i> , 2022, 128, 2025-2035.	4.1	18

#	ARTICLE	IF	CITATIONS
37	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. <i>Thoracic Cancer</i> , 2018, 9, 1519-1521.	1.9	17
38	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). <i>Clinical Lung Cancer</i> , 2021, 22, 147-151.	2.6	16
39	Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers. <i>PLoS ONE</i> , 2021, 16, e0244354.	2.5	16
40	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100107.	1.1	15
41	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 145, 183-193.	2.8	15
42	A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 821-825.	1.3	15
43	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. <i>Oncotarget</i> , 2017, 8, 72127-72132.	1.8	14
44	Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. <i>Cancer Science</i> , 2020, 111, 2482-2487.	3.9	14
45	Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors. <i>Diagnostics</i> , 2020, 10, 949.	2.6	13
46	Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2475-2486.	2.8	13
47	Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. <i>Cancer Science</i> , 2018, 109, 3657-3661.	3.9	12
48	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 472-476.	2.6	12
49	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). <i>Clinical Lung Cancer</i> , 2022, 23, e285-e288.	2.6	12
50	A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 503.	2.6	10
51	CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. <i>Lung Cancer</i> , 2017, 113, 72-78.	2.0	9
52	Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 144-150.	2.0	9
53	IL-6 Induced by Double-Stranded RNA Augments Allergic Inflammation via Suppression of Foxp3+T-Cell/IL-10 Axis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 46, 740-747.	2.9	8
54	Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma. <i>Annals of Hematology</i> , 2018, 97, 359-360.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021, 11, 12732.	3.3	7
56	Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non-small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR. <i>Journal of Clinical Oncology</i> , 2018, 36, e21073-e21073.	1.6	7
57	Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 261.	1.0	6
58	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). <i>Clinical Lung Cancer</i> , 2020, 21, e592-e596.	2.6	5
59	Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy. <i>International Journal of Cancer</i> , 2020, 147, 2327-2334.	5.1	5
60	High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100191.	1.1	5
61	Multiclinality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation. <i>Clinical Lung Cancer</i> , 2020, 21, e21-e24.	2.6	4
62	Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2830-2839.	1.9	4
63	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. <i>Lung Cancer</i> , 2021, 158, 156-161.	2.0	4
64	Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 671-677.	1.1	4
65	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. <i>Lung Cancer</i> , 2018, 126, 156-161.	2.0	3
66	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. <i>Lung Cancer</i> , 2019, 138, 58-64.	2.0	3
67	A measuring method for occupancy of immune checkpoint inhibitors in the cell surface. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 213-217.	2.1	3
68	Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. <i>Clinical Lung Cancer</i> , 2021, 22, e784-e785.	2.6	2
69	Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 8557-8557.	1.6	2
70	Current Situation of Precision Medicine in Lung Cancer. <i>Annals of Oncology</i> , 2018, 29, vii3.	1.2	1
71	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1745-1753.	4.2	1
72	A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L). <i>Journal of Clinical Oncology</i> , 2020, 38, 9597-9597.	1.6	1

#	ARTICLE	IF	CITATIONS
73	A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non-small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).. Journal of Clinical Oncology, 2022, 40, 9097-9097.	1.6	1
74	Paraneoplastic Brainstem Encephalitis and Subacute Sensory Neuropathy Presenting Various Neurological Symptoms Associated with Small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2009, 49, 852-856.	0.1	0
75	Phase I study on safety and PK of rovalpituzumab tesirine (Rova-T) in Japanese patients with advanced, recurrent SCLC. Annals of Oncology, 2018, 29, vii57.	1.2	0
76	Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study.. Journal of Clinical Oncology, 2021, 39, e21125-e21125.	1.6	0
77	5. Current Potential and Clinical Questions of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1117-1124.	0.0	0
78	Final analysis of a phase II, open label, randomized study of osimertinib versus osimertinib plus carboplatin/pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with previous EGFR-TKI and whose tumours harbour a T790M mutation (LOGIK1604/NEJ032A).. Journal of Clinical Oncology, 2020, 38, e21594-e21594.	1.6	0
79	A randomized phase II/ III trial of nivolumab versus nivolumab plus docetaxel for previously treated advanced or recurrent non-small cell lung cancer: TORG1630.. Journal of Clinical Oncology, 2022, 40, 9030-9030.	1.6	0